{"id":"opc-6535-tablets-drug","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL332750","moleculeType":"Small molecule","molecularWeight":"370.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2X7 receptor antagonism reduces ATP-mediated activation of immune cells and inflammatory pathways. This mechanism is being explored to modulate excessive inflammation and immune activation in various disease states. By blocking P2X7 signaling, the drug aims to reduce pathological inflammation while preserving beneficial immune function.","oneSentence":"OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:24:26.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain"},{"name":"Inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT00874497","phase":"PHASE2","title":"Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":84},{"nctId":"NCT00064441","phase":"PHASE3","title":"FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-05","conditions":"Ulcerative Colitis","enrollment":375},{"nctId":"NCT00064454","phase":"PHASE3","title":"FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-05","conditions":"Ulcerative Colitis","enrollment":375},{"nctId":"NCT00092508","phase":"PHASE3","title":"CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-05","conditions":"Ulcerative Colitis","enrollment":1725}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OPC-6535 Tablets (drug)","genericName":"OPC-6535 Tablets (drug)","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses. Used for Neuropathic pain, Inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}